Pedia Loss
This article was originally published in The Tan Sheet
Executive Summary
Feb. 4 congressional letter to pediatric appetite suppressant marketer Dynamic Health Products marks expansion of House Energy & Commerce/Oversight & Investigations Subcommittee inquiry into dietary supplements aimed at children. Letter from Chairman James Greenwood (R-Penn.) follows previous correspondence. Greenwood notes the company previously said Pedia Loss is no longer publicly available, yet the product is still offered on the firm's 1website. Greenwood requests DHP provide records on development, marketing and any adverse events. The subcommittee previously targeted Skinny Pill for Kids. A separate investigation by the subcommittee into ephedra culminated in high-profile hearings which reignited the debate on the adequacy of protections under DSHEA (2"The Tan Sheet" July 28, 2003, p. 5)...
You may also be interested in...
FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.